Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 4
Journal homepage
12
Views
6
CrossRef citations to date
0
Altmetric
Anticancers, Hormonals & Metabolic Disease Therapy

Overview: Diabetes: New Chemical Entities

Robert L Dow Central Research Division, Pfizer Inc, Groton, CT 06340 USA
&
David A Clark Central Research Division, Pfizer Inc, Groton, CT 06340 USA
Pages 349-363 | Published online: 02 Mar 2011

References to Primary Literature

  • Larson ER, Clark DA, Stevenson RW New approaches to diabetes. Ann. Rep. Med. Chem. 1990 25 205.
  • Bailey CJ, Flatt PR New antidiabetic drugs Smith-Gordon London 1990.
  • Stinson SC New drugs under development for diabetes. Chem. Eng. News 1991 69 39 35.
  • De Fronzo RA The triumvirate: β-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 1989 37 667.
  • Olefsky JM, Garvey WT, Henry RR, Matthaei S, Freidenberg GR Cellular mechanisms of insulin-resistance in non-insulin dependent (type II) diabetes. Am. J. Med. 1988 85 Suppl 5A 86.
  • Kahn CR Insulin resistance, insulin sensitivity, and insulin unresponsiveness: A necessary distinction. Metabolism 1978 27 Suppl 2 1893.
  • Olefsky JM, Kolterman OG, Scarlett JA Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am. J. Physiol. 1982 243 E15.
  • De Fronzo RA, Ferrannini E, Koviosto U.V New concepts in the pathogenesis and treatment of non-insulin-diabetes mellitus. Am. J. Med. 1983 74 Suppl 1A 52.
  • Sohda T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T, Kawamatsu Y Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem. Pharm. Bull. 1982 30 3580.
  • Colca JR, Kunoh Y, Antihyperglycaemic thiazolidinediones: Ciglitazone and its analogs, New Antidiabetic Drugs Bailey CJ Flatt PR Smith-Gordon 1990 255 For a review see.
  • Shargill NS, Tatoyan A, Fukushima M, Antui D, Bray GA, Chan TM Effects of ciglitazone on glucose uptake and insulin sensitivity in skeletal muscle of the obese (ob/ob) mouse: Distinct insulin and glucoconicoid effects. Metabolism 1986 35 64.
  • Chang AY, Wyse BM, Gilchrist BJ Ciglitazone, a new hypoglycemic agent: II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. Diabetes 1983 32 839.
  • Mercer SW, Trayhurn P Effects of ciglitazone on insulin resistance and thermogenic responsiveness to acute cold in brown adipose tissue of genetically obese (ob/ob) mice. FEBS Lett. 1986 195 12.
  • Kraegen EW, James DE, Lenkins AB, Chisholm DJ, Storlien LH A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding in rats. Metabolism 1989 38 1089.
  • Martz A, Jo I, Jung CY Sulphonylurea binding to adipocyte membranes and potentiation of insulin-stimulated hexose kinase. J. Biol. Chem. 1989 264 13672.
  • Joost HG, Weber TM The regulation of glucose transport in insulin-sensitive cells. Diabetologia 1989 32 831.
  • Doi K Application of AD-3878 to treatment of diabetes. Tohnyobo 1982 25 397.
  • Baba S, Doi K, Matsuura M, Kawara A, Tanaka T, Ooe M New antidiabetic agent AD-3878. Diabetes 1982 31 Suppl 2 77A.
  • Doi K New orally active hypoglycemic agent. Nippon Rinshio 1986 44 Suppl. 447.
  • Sohda T, Meguro K, Kawamatsu Y, Ikeda H, Fujita T A new antidiabetic agent AD-4833, and structure-activity relationships of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinedione. J. Pharm. Sci. 1987 76 S/173.
  • Momose Y, Meguro K, Ikeda H, Hatanaka C, Oi S, Sohda T Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull. 1991 39 6 1440.
  • Colca JR, Dailey CF, Palazuk BJ, Hillman RM, Dinh DacM, Melchior GW, Spilman CH Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats. Diabetes 1991 40 1669.
  • Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991 14 11 1083.
  • Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H Studies on hindered phenols and analogs. I. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. 1989 32 421.
  • Fujiwara I, Yoshioka T, Ushiyama I, Horikoshi H Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988 37 1549.
  • Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990 39 10 1056.
  • Clark DA, Goldstein SW, Hulin B, Volkmann RA, Eggler JF, Holland GF, Stevenson RW, Kreutter DK, Gibbs EM, Krupp MK, Johnson MR, Hutson NJ, Synthesis and SAR of substituted dihydrobenzpyran and dihydrobenzofuran thiazolidine-2,4-di-ones for hypoglycemic activity. 199th American Chemical Society Meeting Boston, MA, April, 1990.
  • Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Johnson MR, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, Gibbs EM, Kreutter DK Actions of the novel antidiabetic agent CP-68722, in the hyperglycemic, hyperinsulinemic ob/ob mouse. Diabetes 1990 39 1218.
  • Kreutter DK, Andrews KM, Gibbs EM, Stevenson RW, Hutson NJ Insulin-like activity of a new antihyperglycaemic agent CP-68722, in 3T3-Ll adipocytes. Diabetologia 1989 32 506A.
  • Gibbs EM, Genereux PE, Kreutter DK, Andrews KM, Stevenson RW A novel antidiabetic agent, CP-68722, increases levels of glucose transport and glucose transporter protein in 3T3-L1 adipocytes. Diabetologia 1989 32 491A.
  • Clark DA, Goldstein SW, Volkmann RA, Eggler JF, Holland GF, Hulin B, Stevenson RW, Kreutter DK, Gibbs EM, Krupp MN, Merrigan P, Kelbaugh PL, Andrews EG, Tickner DL, Suleske RT, Lamphere CH, Rajeckas FJ, Kappeler WH, McDermott RE, Hutson NJ, Johnson MR Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. J. Med Chem. 1991 34 319.
  • Dow RL, Bechle BM, Chou TT, Clark DA, Hulin B, Stevenson RW Benzyloxazolidinedine-2,4-diones as potent hypoglycemic agents. J. Med. Chem. 1991 34 1538.
  • Zask A, Jirkovsky I, Nowicki JW, McCaleb M Synthesis and antihyperglycemic activity of novel 5-(napthalenyl sulphonyl)-2,4-thia-zolidinediones. J. Med. Chem. 1990 33 1418.
  • Elbein AD Glycosidase inhibitors: Inhibitors of N-linked oligosaccharide processing. FASEB J. 1991 5 3055.
  • Jenkins DJA, Taylor RH, Goff DV, Fielden H., Misiewicz JJ, Sarson DL, Bloom SR, Alberti KGMM Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981 30 951.
  • Lembke B, Foelsch UR, Creutzfeldt W Effect of L-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Digestion 1985 31 109.
  • Taylor RH, α-Glucosidase inhibitors, New antidiabetic drugs Bailey CJ Flatt PR Smith-Gordon London 1990 119 Development of Emiglitate was ceased in Phase II, see.
  • Rhinehart BL, Robinson KM, Liu PS, Payne ME, Wheatley ME, Wagner SR Inhibition of intestinal disaccharidases and suppression of blood glucose by a new α-glucohydrolase inhibitor-MDL 25,637. J. Pharmacol. Exp. Ther. 1987 241 915.
  • Danzin C, Ehrhard A Time-dependent inhibition of sucrase and isomaltase from rat small intestine by castanospermine. Arch. Biochem. Biophys. 1987 257 472.
  • Fleet GWL, Nicholas SJ, Smith PW, Evans SV, Fellows LE, Nash RJ Potent competitive inhibition of α-galactosidase and α-glucosidase activity by 1,4-dideoxy-1,4-iminopentitols: Syntheses of 1,4-dideoxy-1,4-imino-D-lyxitol and of both enantiomers of 1,4-dideoxy-1,4-iminoarabinitol. Tetrahedron Lett. 1985 26 3127.
  • Ruderman NB, Ganda OP, Johanson K The effect of physical training on glucose tolerance and plasma lipids in maturity onset diabetes. Diabetes 1979 28 suppl 89.
  • Scheidegger K, Robbins DC, Sanforth E Effects of chronic β-receptor stimulation on glucose metabolism. Diabetes 1984 33 1144.
  • Arch JRS, Ainsworth AT, Cawthome MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S Atypical β-adrenoceptor in brown adipocytes as target for antiobesity drugs. Nature 1984 309 163.
  • Emorine LJ, Marullo S, Briend-Sutren MM, Pates G, Tate K, Delavier-Dlutchko C, Strosberg AD Molecular characterization of the human β3-adrenonergic receptor. Science 1989 245 1118.
  • Smith SA, Sennitt MV, Cawthome MA, BRL 35135: An orallly active antihyperglycaemic agent with height reducing effects, New Antidiabetic Drugs Bailey CJ Flatt PR Smith-Gordon 1990 177 For a review on BRL 35135 see.
  • Holloway BR, Howe R, Rao BS, Stribling D, ICI 198157: A novel selective agonist of brown fat and thermogenesis, Obesity in Europe Bjorntorp P Rossner S John Libbey London 1989 88.
  • Ruffolo RR, Nichols AJ, Hieble JP Metabolic regulation by α1- and α2-adrenoceptors. Life Sci. 1990 49 3 171.
  • Drugs of the Future 1990 15 8 856.
  • Chan SLF, Stillings MR, Morgan NG Mechanisms involved in stimulation of insulin secretion by the hypoglycemic alpha-adrenergic antagonist, DG-5128. Biochem. Biophys. Res. Commun. 1991 176 3 1545.
  • Atlas D Clonidine-displacing substance (CDS) and its putative imidazoline receptor. Biochem. Pharmacol. 1991 41 11 1541.
  • Henquin JC, Established, unsuspected, and novel pharmacological insulin secretogogues, New Antidiabetic Drugs Bailey CJ Flatt PR Smith-Gordon 1990 93.
  • Mendola G, Casamitjana R, Gomis R Effect of nicotinamide therapy upon B-cell function in newly diagnosed Type I (insulin-dependent) diabetic patients. Diabetologia 1989 32 160.
  • Schechter Y, Karlish SJD Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature 1980 284 556.
  • Heylinger CE, Tahiliani AG, McNeill JH Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 1985 227 1474.
  • Gammeltoft S, Van Obberghen E Protein kinase activity of the insulin receptor. Biochem. J. 1986 235 1.
  • Leighton B, Cooper GJ The role of amylin in the insulin resistance of noninsulin-dependent diabetes mellitus. Trends Biochem. Sci. 1991 15 295.
  • Moore CX, Cooper GJ Co-secretion of amyllin and insulin from cultured islet βcells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem. Biophys. Res. Commun. 1991 179 1 1.
  • Weir GC, Mojsov S, Hendrick GK, Habener JF Glucagonlike peptide I (7–37) actions on endocrine pancreas. Diabetes 1989 38 338.
  • Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7–36)Amide. Diabetes 1989 38 902.
  • Yen TT, Dominianni SJ, Harris RA, Stephens TW, Antihyperglycaemic phenacyl imidazolium compounds stabalize hepatic glycogen, New Antidiabetic Drugs Bailey CJ Flatt PR Smith-Gordon 1990 245.
  • Harris RA, Yamanouchi K, Roach PJ, Yen TT, Dominianni SJ, Stephens TW Stabalization of glycogen stores and stimulation of glycogen synthesis in hepatocytes by phenacyl imidazolium compounds. J. Biol. Chem. 1989 264 25 14674.
  • Yen TT, Kunoh Y, Antihyperglycaemic activities of thiopyranopyrimidine derivatives, New Antidiabetic Drugs Bailey CJ Flatt PR Smith-Gordon 1990 263 For a review see.
  • Yen TT, Dininger NB, Broderick AM, Gill AM Antidiabetic activity of MTP-3115 in normal and diabetic mice. Arch. Int. Pharmacodyn. 1990 308 137.
  • Bailey CJ, Day C Traditional plant medicines as treatments for diabetes. Diabetes Care 1989 12 553.
  • Farnsworth NR, The role of medicinal plants in drug development, Natural products and drug development Krogsgaardlarsen P Brogger-Christensen S Kofod H Minksgaard Copenhagen 1983 15.
  • Undie AS, Akubue PL Pharmacological evaluation of dioscorea-dumetorum tuber used in traditional antidiabetic therapy. J. Ethnopharm. 1986 15 133.
  • Iwu MM, Okunji CO, Akah P, Tempesta MS, Corley D Dioscoretine: The hypoglycemic principle of dioscorea dumetorum. Planta Med. 1990 56 119.
  • Kennedy WB, Lukens FDW Observations on allocan diabetes. Proc. Soc. Biol. Med. 1944 57 143.
  • Larson ER, Lipinski CA, Sarges R Medicinal chemistry of aldose reductase inhibitors. Medicinal Res. Rev. 1988 8 159.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.